Florent Aptel1,2,3,4, Nischal Aryal-Charles5,6, Renaud Tamisier5,7, Jean-Louis Pépin5,7, Antoine Lesoin5,6, Christophe Chiquet5,6,7. 1. Université Grenoble Alpes, F-38041, Grenoble, France. faptel@chu-grenoble.fr. 2. Clinique Universitaire d'Ophtalmologie, CHU de Grenoble, 38043, Grenoble cedex 09, France. faptel@chu-grenoble.fr. 3. Department of Ophthalmology, University Hospital, CHU Grenoble, F-38043, Grenoble, France. faptel@chu-grenoble.fr. 4. INSERM U1042, Lab Hypoxia and Physiopathology, Université Grenoble Alpes, Grenoble, France. faptel@chu-grenoble.fr. 5. Université Grenoble Alpes, F-38041, Grenoble, France. 6. Department of Ophthalmology, University Hospital, CHU Grenoble, F-38043, Grenoble, France. 7. INSERM U1042, Lab Hypoxia and Physiopathology, Université Grenoble Alpes, Grenoble, France.
Abstract
PURPOSE: To evaluate whether obstructive sleep apnea (OSA) is responsible for the visual field defects found in the fellow eyes of patients with non-arteritic ischemic optic neuropathy (NAION). METHODS: Prospective cross-sectional study. The visual fields of the fellow eyes of NAION subjects with OSA were compared to the visual fields of control OSA patients matched for OSA severity. All patients underwent comprehensive ophthalmological and general examination including Humphrey 24.2 SITA-Standard visual field and polysomnography. Visual field defects were classified according the Ischemic Optic Neuropathy Decompression Trial (IONDT) classification. RESULTS: From a cohort of 78 consecutive subjects with NAION, 34 unaffected fellow eyes were compared to 34 control eyes of subjects matched for OSA severity (apnea-hypopnea index [AHI] 35.5 ± 11.6 vs 35.4 ± 9.4 events per hour, respectively, p = 0.63). After adjustment for age and body mass index, all visual field parameters were significantly different between the NAION fellow eyes and those of the control OSA groups, including mean deviation (-4.5 ± 3.7 vs -1.3 ± 1.8 dB, respectively, p < 0.05), visual field index (91.6 ± 10 vs 97.4 ± 3.5%, respectively, p = 0.002), pattern standard deviation (3.7 ± 2.3 vs 2.5 ± 2 dB, respectively, p = 0.015), and number of subjects with at least one defect on the IONDT classification (20 vs 10, respectively, p < 0.05). CONCLUSIONS: OSA alone does not explain the visual field defects frequently found in the fellow eyes of NAION patients.
PURPOSE: To evaluate whether obstructive sleep apnea (OSA) is responsible for the visual field defects found in the fellow eyes of patients with non-arteritic ischemic optic neuropathy (NAION). METHODS: Prospective cross-sectional study. The visual fields of the fellow eyes of NAION subjects with OSA were compared to the visual fields of control OSA patients matched for OSA severity. All patients underwent comprehensive ophthalmological and general examination including Humphrey 24.2 SITA-Standard visual field and polysomnography. Visual field defects were classified according the Ischemic Optic Neuropathy Decompression Trial (IONDT) classification. RESULTS: From a cohort of 78 consecutive subjects with NAION, 34 unaffected fellow eyes were compared to 34 control eyes of subjects matched for OSA severity (apnea-hypopnea index [AHI] 35.5 ± 11.6 vs 35.4 ± 9.4 events per hour, respectively, p = 0.63). After adjustment for age and body mass index, all visual field parameters were significantly different between the NAION fellow eyes and those of the control OSA groups, including mean deviation (-4.5 ± 3.7 vs -1.3 ± 1.8 dB, respectively, p < 0.05), visual field index (91.6 ± 10 vs 97.4 ± 3.5%, respectively, p = 0.002), pattern standard deviation (3.7 ± 2.3 vs 2.5 ± 2 dB, respectively, p = 0.015), and number of subjects with at least one defect on the IONDT classification (20 vs 10, respectively, p < 0.05). CONCLUSIONS: OSA alone does not explain the visual field defects frequently found in the fellow eyes of NAIONpatients.
Authors: Vincent A Deramo; Robert C Sergott; James J Augsburger; Rod Foroozan; Peter J Savino; Anthony Leone Journal: Ophthalmology Date: 2003-05 Impact factor: 12.079
Authors: Steven E Feldon; Lori Levin; Roberta W Scherer; Anthony Arnold; Sophia M Chung; Lenworth N Johnson; Gregory Kosmorsky; Steven A Newman; Joanne Katz; Patricia Langenberg; P David Wilson; Shalom E Kelman; Kay Dickersin Journal: BMC Ophthalmol Date: 2006-11-20 Impact factor: 2.209